Article
Inhibition of type I histone deacetylase increases resistance of checkpoint-deficient cells to genotoxic agents through mitotic delay.
Molecular cancer therapeutics - 1 Sept 2009
Alao John P, Olesch Jeanette, Sunnerhagen Per
Abstract excerpt
Histone deacetylase (HDAC) inhibitors potently inhibit tumor growth and are currently being evaluated for their efficacy as chemosensitizers and radiosensitizers. This efficacy is likely to be limited by the fact that HDAC inhibitors also induce cell cycle arrest. Deletion of the class I HDAC Rpd3 has been shown to specifically suppress the sensitivity of Saccharomyces cerevisiae DNA damage checkpoint mutants to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.